Key result
The use of inotropic agents in heart failure remains controversial due to a lack of uniform data, highlighting the need for adequately powered prospective randomized trials.
This overview highlights the ongoing controversies and lack of uniform data regarding the use of inotropic agents in heart failure, emphasizing the need for adequately powered randomized trials.
The use of inotropic agents has been surrounded by many controversies. Recent guidelines for the treatment of patients with chronic and acute heart failure have elucidated some of the issues, but many remain. As a result, a substantial variability in the use of agents between institutions and caregivers remains, which mainly results from the lack of uniform data in the literature. Prospective randomized trials with a long-term follow-up and sufficient power are clearly needed, and a number of trials are currently in progress.
No takes yet. Share an insight, caveat, or question.
Margreeth B. Vroom (2006) conducted a review in Chronic and acute heart failure. Inotropic agents was evaluated. The use of inotropic agents in heart failure remains controversial due to a lack of uniform data, highlighting the need for adequately powered prospective randomized trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: